Oneness announces that LEO PHARMA made the 2nd upfront payment of US$15.12MM according to the agreement. A total of US$33.6MM upfront payments have been received.

Published Date:2021-01-14

Statement
No	1	Date of announcement	2021/01/14	Time of announcement	17:17:29
Subject	Oneness announces that LEO PHARMA made the 2nd upfront payment of US$15.12MM according to the agreement. A total of US$33.6MM upfront payments have been received.
To which item it meets	paragraph 53			Date of events	2021/01/14
1.Date of occurrence of the event:2021/01/14 2.Company name:Oneness Biotech Co., Ltd. 3.Relationship to the Company (please enter ”head office” or ”subsidiaries”):head office 4.Reciprocal shareholding ratios:NA 5.Cause of occurrence: (1)Oneness Biotech and Microbio (Shanghai) Entered a worldwide exclusive license agreement with LEO Pharma A/S for FB825, a first-in-class antibody for allergic diseases. (2)LEO PHARMA A/S has made a payment of the 2nd upfront fee of US$15.12 million (US$13.608 million after tax) according to the agreement. The upfront payments in a total US$33.60 million (US$30.24 million after tax) have all been received. 6.Countermeasures:None 7.Any other matters that need to be specified:The received upfront payments shall be recognized upon completion of Phase IIa study in the atopic dermatitis in the United States according to the relevant provisions of Revenue from Contracts with Customers of IFRS#15.